First Horizon Advisors Inc. Has $45,000 Stock Position in ShockWave Medical, Inc. (NASDAQ:SWAV)

First Horizon Advisors Inc. boosted its position in ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) by 67.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 260 shares of the company’s stock after purchasing an additional 105 shares during the period. First Horizon Advisors Inc.’s holdings in ShockWave Medical were worth $45,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. C M Bidwell & Associates Ltd. acquired a new stake in ShockWave Medical in the 3rd quarter valued at about $38,000. PNC Financial Services Group Inc. lifted its stake in ShockWave Medical by 30.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 202 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. National Asset Management Inc. acquired a new stake in ShockWave Medical in the 3rd quarter valued at about $206,000. Raymond James Financial Services Advisors Inc. lifted its stake in ShockWave Medical by 15.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 1,165 shares of the company’s stock valued at $208,000 after purchasing an additional 152 shares during the last quarter. Finally, Sawtooth Solutions LLC acquired a new stake in ShockWave Medical in the 3rd quarter valued at about $252,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

In related news, VP Trinh Phung sold 3,176 shares of the stock in a transaction that occurred on Tuesday, April 12th. The shares were sold at an average price of $215.61, for a total transaction of $684,777.36. Following the sale, the vice president now owns 29,695 shares in the company, valued at approximately $6,402,538.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Antoine Papiernik sold 60,000 shares of the stock in a transaction that occurred on Thursday, March 10th. The stock was sold at an average price of $163.38, for a total transaction of $9,802,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 119,242 shares of company stock worth $19,662,635 in the last quarter. 15.30% of the stock is currently owned by company insiders.

Shares of SWAV opened at $162.32 on Friday. ShockWave Medical, Inc. has a 12 month low of $113.36 and a 12 month high of $249.73. The firm’s 50 day moving average is $179.06 and its 200-day moving average is $178.37. The stock has a market capitalization of $5.81 billion, a PE ratio of 210.81 and a beta of 1.50. The company has a current ratio of 6.07, a quick ratio of 4.71 and a debt-to-equity ratio of 0.03.

ShockWave Medical (NASDAQ:SWAVGet Rating) last announced its earnings results on Monday, May 9th. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.19 by $0.20. ShockWave Medical had a net margin of 9.70% and a return on equity of 12.36%. The company had revenue of $93.70 million for the quarter, compared to analysts’ expectations of $86.41 million. During the same period last year, the firm earned ($0.68) earnings per share. The business’s revenue for the quarter was up 193.7% on a year-over-year basis. Equities research analysts predict that ShockWave Medical, Inc. will post 1.68 earnings per share for the current fiscal year.

Several brokerages recently issued reports on SWAV. Wells Fargo & Company cut their target price on shares of ShockWave Medical from $235.00 to $176.00 in a research note on Tuesday. Bank of America started coverage on shares of ShockWave Medical in a report on Wednesday, March 2nd. They issued a “buy” rating on the stock. Piper Sandler lowered their price target on shares of ShockWave Medical from $272.00 to $245.00 in a report on Friday, February 18th. SVB Leerink increased their price target on shares of ShockWave Medical from $160.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, February 18th. Finally, Canaccord Genuity Group lowered their price target on shares of ShockWave Medical from $221.00 to $190.00 in a report on Tuesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ShockWave Medical presently has an average rating of “Buy” and an average price target of $212.89.

About ShockWave Medical (Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Featured Stories

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.